Results 1 to 10 of about 118,941 (325)

Sodium-glucose co-transporter 2 inhibitors – a review article [PDF]

Journal of Education, Health and Sport, 2019
Antihyperglycemic interventions have centered on increasing insulin availability, improving insulin sensitivity or restoring β-cell activity to normalize plasma glucose levels in patients with type 2 diabetes mellitus.
Marcin Makuch, Marcelina Makuch, Ewa Krzewicka-Romaniuk, Grzegorz Dzida   +3 more
doaj   +7 more sources

Effect of sodium-glucose Co-transporter 2 inhibitors on coronary microcirculation [PDF]

Frontiers in Pharmacology
Coronary microvascular disease (CMVD) has emerged as a new target for the occurrence and development of heart failure treatment. Various indicators such as Index of Microvascular Resistance, Coronary Flow Reserve, Microvascular Resistance Reserve ...
Shaoxin Chen, Weiqian Ou, Shuguang Gan, Lixian Chen, Baohua Liu, Zhenhong Zhang   +5 more
doaj   +4 more sources

Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors

Frontiers in Pharmacology, 2022
Arrhythmias are clinically prevalent with a high mortality rate. They impose a huge economic burden, thereby substantially affecting the quality of life.
Yuling Jing, Ruixue Yang, Wen Chen, Qiang Ye   +3 more
doaj   +3 more sources

The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes [PDF]

Nature Communications
Diabetes is common in patients with chronic obstructive pulmonary disease. Sodium-glucose co-transporter-2 inhibitors are effective in treating type 2 diabetes and provide benefits for conditions like cardiovascular and kidney diseases.
Jheng-Yan Wu, Khai-Chi Hu, Mei-Yuan Liu, Yu-Jou Wu, Wan-Hsuan Hsu, Ya-Wen Tsai, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Kuang-Ming Liao, Chih-Cheng Lai   +11 more
doaj   +2 more sources

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis [PDF]

PLoS ONE, 2016
Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treatment of diabetes. We aimed at describing the maximal benefits and risks associated with SGLT2-i for patients with type 2 diabetes.Systematic review and meta-analysis.
A Berhan, A Lewin, A Liakos, A Patel, AK Singh, B Bode, B Bode, B Neal, B Zinman, C Mathieu, C Sonesson, C Triplitt, Cathy Bennett, CJ Bailey, CJ Bailey, CJ Bailey, CS Kovacs, CS Kovacs, D Moher, D Vasilakou, DS Shyangdan, E Ferrannini, E Ferrannini, E Ferrannini, E Ferrannini, E Ferrannini, F Zaccardi, Filip K. Knop, FJ Lavalle-Gonzalez, G Guyatt, G Musso, G Schernthaner, H Liu, H Storgaard, H Storgaard, Heidi Storgaard, HJ Lambers Heerspink, HU Haering, HU Haring, HU Haring, IM Stratton, J Bolinder, J Bolinder, J Rosenstock, J Rosenstock, J Rosenstock, J Rosenstock, J Rosenstock, J Rosenstock, J Yoon, JF List, JH Wu, JP Wilding, JP Wilding, JP Wilding, JP Wilding, K Damman, K Kaku, K Kaku, K Stenlof, K Stenlof, K Strojek, K Strojek, L Ji, L Merker, LA Leiter, LA Leiter, LA Leiter, Lise L. Gluud, M Laakso, M Ridderstrale, M Ridderstråle, M Roden, M Sarnak, MA Nauck, MA Nauck, Magnus F. Grøndahl, MH Ahmed, Mikkel B. Christensen, N Inagaki, Noel Christopher Barengo, O Ljunggren, P Gaede, P Jose, RA DeFronzo, RR Henry, RR Holman, S Del Prato, S Goring, S Kalra, S Matthaei, S Matthaei, S Ross, SA Jabbour, SE Inzucchi, SE Kahn, T Forst, T Kadowaki, Tina Vilsbøll, W Duckworth, WL Baker, WT Cefalu, WT Cefalu, Y Yilmaz   +103 more
core   +4 more sources

Impact of Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Exercise‐Induced Pulmonary Hypertension [PDF]

Pulmonary Circulation
Patients with borderline pulmonary hypertension (PH) often experience shortness of breath or exacerbation of PH during exercise, known as exercise‐induced PH.
Taijyu Satoh, Nobuhiro Yaoita, Satoshi Higuchi, Kotaro Nochioka, Saori Yamamoto, Haruka Sato, Shunsuke Tatebe, Kaito Yamada, Yusuke Yamada, Kohei Komaru, Naoki Chiba, Yuki Sarashina, Ryuichi Mori, Mitsuru Nakada, Hideka Hayashi, Hideaki Suzuki, Hiroyuki Takahama, Hideki Ota, Satoshi Yasuda   +18 more
doaj   +2 more sources

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Cardiovascular Diabetology, 2018
Diabetes mellitus currently affects over 350 million patients worldwide and is associated with many deaths from cardiovascular complications. Sodium–glucose co-transporter 2 (SGLT-2) inhibitors are a novel class of antidiabetic drugs with cardiovascular ...
Sarayut Lahnwong, Siriporn C. Chattipakorn, Nipon Chattipakorn   +2 more
doaj   +2 more sources

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

The Lancet, 2022
Summary Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high ...
C. Baigent, J. Emberson, R. Haynes, W. Herrington, P. Judge, M. Landray, Kaitlin J. Mayne, S. Ng, D. Preiss, A. Roddick, N. Staplin, D. Zhu, S. Anker, Deepak L. Bhatt, M. Brueckmann, J. Butler, D. Cherney, Jennifer B. Green, S. Hauske, H. Heerspink, S. Inzucchi, M. Jardine, Chih-Chin Liu, K. Mahaffey, Finnian R. McCausland, D. McGuire, J. McMurray, B. Neal, B. Neuen, M. Packer, V. Perkovic, M. Sabatine, S. Solomon, M. Vaduganathan, C. Wanner, D. Wheeler, S. Wiviott, F. Zannad   +37 more
semanticscholar   +1 more source

A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors.

Cell Metabolism, 2021
Sodium glucose co-transporter (SGLT) 2 inhibitors reduce the risk of kidney failure in patients with and without type 2 diabetes (T2D). Although the precise underlying mechanisms for these nephroprotective effects are incompletely understood, various ...
T. Sen, H. Heerspink
semanticscholar   +1 more source

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction

European Journal of Heart Failure, 2021
Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a foundational therapy for patients with heart failure (HF) and reduced ejection fraction (HFrEF) because of their favourable effects on mortality, clinical events and ...
D. Tomasoni, G. Fonarow, M. Adamo, S. Anker, J. Butler, A. Coats, G. Filippatos, S. Greene, T. McDonagh, P. Ponikowski, G. Rosano, P. Seferovic, M. Vaduganathan, A. Voors, M. Metra   +14 more
semanticscholar   +1 more source